In focus · trending topic

PNH

41 stories · following the connections

Akari Therapeutics Announces Receipt of Orphan Drug Designation for Coversin from the U.S. FDA for Treatment of Paroxysmal Nocturnal Hemoglobinuria

By Nasdaq OMXSep 12, 2016, 11:15 AM UTC

Achillion Presents Novel Research on Factor D Inhibition at the XXVIth International Complement Workshop

By Nasdaq OMXSep 6, 2016, 10:05 AM UTC

Achillion to Present at Two Upcoming Investor Conferences

By Nasdaq OMXSep 1, 2016, 10:05 AM UTC

Achillion to Present at the 2016 Wedbush PacGrow Healthcare Conference

By Nasdaq OMXAug 9, 2016, 10:05 AM UTC

Akari Therapeutics Announces Positive Preliminary Results from First PNH Patient Treated With Coversin

By Nasdaq OMXMar 31, 2016, 8:03 PM UTC

Achillion Reports 2015 Fourth Quarter and Year-End Financial Results

By Nasdaq OMXFeb 25, 2016, 11:05 AM UTC

Achillion Initiates Phase 1 Study of ACH-4471, First Orally-Administered Small Molecule Complement Factor D Inhibitor

By Nasdaq OMXFeb 11, 2016, 11:05 AM UTC

Achillion Announces Appointments of Martha Manning as General Counsel and Amy Jennings as Head of Regulatory Affairs

By Nasdaq OMXFeb 3, 2016, 11:05 AM UTC